Experimental Treatments for Myasthenia Gravis

Batoclimab is an experimental antibody therapy being developed for the treatment of a number of autoimmune diseases, including generalized MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to lower the levels of MG-causing antibodies in order to ease disease severity.

CABA-201 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a one-time intravenous, or into-the-bloodstream, infusion after a course of chemotherapy, the therapy is designed to target disease-driving immune B-cells to potentially reduce MG severity.

Cladribine is a short-course oral therapy being developed for generalized MG. Administered as oral capsules, it’s designed to lower the levels of the immune cells that drive inflammatory attacks in MG.

Descartes-08 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions, it is designed to lower the levels of immune B-cells and potentially reduce disease severity.

DNTH103 is an investigational antibody-based therapy being developed for the treatment of generalized MG. Administered in the form of subcutaneous, or under-the-skin, injections that can be self-administered, it is designed to block the activation of the complement system, a part of the immune system thought to contribute to disease’s autoimmune attacks.

Gefurulimab is an experimental therapy being developed for the treatment of generalized MG. Administered in the form of subcutaneous, or under-the-skin, injections that can be self-administered, it is designed to block the activation of the complement system, a part of the immune system that’s thought to be involved in the disease’s autoimmune attacks.

Inebilizumab is an antibody-based therapy being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions every six months, the therapy is expected to reduce the levels of certain immune cells that drive MG and ease disease symptoms.

KYV-101 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a single infusion into the bloodstream, or intravenously, after a short course of chemotherapy, it is designed to lower the levels of immune B-cells and potentially ease disease severity.

MuSK-CAART is an investigational T-cell therapy that’s being developed for the treatment of MG patients positive for anti-MuSK antibodies. Administered via a one-time intravenous, or into-the-vein, infusion, the therapy is designed to eliminate the specific immune B-cells that produce those self-reactive antibodies.

Nipocalimab is an experimental antibody therapy being developed for the treatment of a number of autoimmune diseases, including generalized MG. The therapy, administered via into-the-vein (intravenous) infusions, is designed to lower the levels of MG-causing antibodies in order to ease disease severity.

NMD670 is an investigational oral therapy being developed for MG and a number of rare diseases. The therapy, administered twice daily in the form of oral tablets, is designed to improve nerve-muscle communication and restore muscle function.

A combination of the antibody therapy pozelimab and an RNA-based therapy called cemdisiran is being developed for the treatment of MG. Administered in the form of monthly subcutaneous, or under-the-skin, injections, the combination is designed to block the activation of the complement system, a part of the immune system thought to be involved in the disease’s autoimmune attacks.

Rituximab is an antibody-based therapy that’s approved for some blood cancers and autoimmune conditions. It is not formally approved for the treatment of MG, but it may be used off-label in some patients with treatment-resistant disease. The therapy is administered via intravenous, or into-the-vein, infusions.

Telitacicept is an investigational B-cell targeting therapy being developed as a potential treatment for MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to reduce the activity of immune B-cells that drive MG.